Coherus Oncology, Inc. (CHRS) Competitors & Peers
The 5 companies closest to Coherus Oncology, Inc. on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $523.91 | P/E 30.5RSI 70Cap 132.7 B |
| REGN | Peer | $808.05 | P/E 19.4RSI 83Cap 83.2 B |
| ARGX | Peer | $866.16 | P/E 31.6RSI 40Cap 51.8 B |
| RVMD | Peer | $202.93 | RSI 60Cap 39.4 B |
| CSLLY | Peer | $23.77 | P/E 15.4RSI 68Cap 45.5 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- DSNKYSupplier
Own 10-Q customer-concentration disclosure: DaiichiSankyo = 10% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CAHSupplier
Own 10-K customer-concentration disclosure: Cardinal = 18% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
Own 10-K customer-concentration disclosure: McKesson = 42% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - BAXSupplier
Own 10-Q customer-concentration disclosure: Baxter = 91% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - BXLTSupplier
Own 10-Q customer-concentration disclosure: BaxaltaCorporation = 94% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- IQVPartner
IQVIA provides contract clinical research and trial management services (CRO).
Model-inferred, unverified — treat as a lead, not evidence - AMZNSupplier
Utilizes AWS cloud infrastructure to host genomic sequencing data and clinical trial databases.
Model-inferred, unverified — treat as a lead, not evidence - PFECompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence